Liệu pháp thay thế hormone sau mãn kinh và xơ vữa động mạch

American Heart Association: 2001 Heart and Stroke Statistical Update. Dallas, Texas: American Heart Association. 2000. Kannel WB, Wilson PW: Risk factors that attenuate the female coronary disease advantage. Arch Intern Med 1995, 155:57–61. Mendelsohn ME, Karas RH: The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999, 340:1801–1811. Losordo DW, Kearney M, Kim EA, Jekanowski J, Isner JM: Variable expression of the estrogen receptor in normal and atherosclerotic coronary arteries of premenopausal women. Circulation 1994, 89:1501–1510. Zhu Y, Bian Z, Lu P, et al.: Abnormal vascular function and hypertension in mice deficient in estrogen receptor beta. Science 2002, 295:505–508. Chen Z, Yuhanna IS, Galcheva-Gargova Z, et al.: Estrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. J Clin Invest 1999, 103:401–406. Haynes MP, Sinha D, Russell KS, et al.: Membrane estrogen receptor engagement activates endothelial nitric oxide synthase via the PI3-kinase-Akt pathway in human endothelial cells. Circ Res 2000, 87:677–682. Simoncini T, Hafezi-Moghadam A, Brazil DP, et al.: Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 2000, 407:538–541. Espeland MA, Marcovina SM, Miller V, et al.: Effect of postmenopausal hormone therapy on lipoprotein(a) concentration. PEPI Investigators. Postmenopausal Estrogen/Progestin Interventions. Circulation 1998, 97:979–986. The Writing Group for the PEPI Trial: Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995, 273:199–208. Brinton EA: Oral estrogen replacement therapy in postmenopausal women selectively raises levels and production rates of lipoprotein A-I and lowers hepatic lipase activity without lowering the fractional catabolic rate. Arterioscler Thromb Vasc Biol 1996, 16:431–440. Nabulsi AA, Folsom AR, White A, et al.: Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. The Atherosclerosis Risk in Communities Study Investigators. N Engl J Med 1993, 328:1069–1075. Sack MN, Rader DJ, Cannon RO 3rd: Oestrogen and inhibition of oxidation of low-density lipoproteins in postmenopausal women. Lancet 1994, 343:269–270. Mendelsohn ME, Karas RH: Estrogen and the blood vessel wall. Curr Opin Cardiol 1994, 9:619–626. White RE, Darkow DJ, Lang JL: Estrogen relaxes coronary arteries by opening BKCa channels through a cGMP-dependent mechanism. Circ Res 1995, 77:936–942. Koh KK, Home MK 3rd, Cannon RO 3rd: Effects of hormone replacement therapy on coagulation, fibrinolysis, and thrombosis risk in postmenopausal women. Thromb Haemost 1999, 82:626–633. Cushman M, Legault C, Barrett-Connor E, et al.: Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation 1999, 100:717–722. Agrawal R, Prelevic G, Conway GS, et al.: Serum vascular endothelial growth factor concentrations in postmenopausal women: the effect of hormone replacement therapy. Fertil Steril 2000, 73:56–60. Walsh BW, Paul S, Wild RA, et al.: The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 2000, 85:214–218. Vehkavaara S, Westerbacka J, Hakala-Ala-Pietila T, et al.: Effect of estrogen replacement therapy on insulin sensitivity of glucose metabolism and preresistance and resistance vessel function in healthy postmenopausal women. J Clin Endocrinol Metab 2000, 85:4663–4670. Grady D, Wenger NK, Herrington D, et al.: Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progest in Replacement Study. Ann Intern Med 2000, 132:689–696. Braunstein JB, Kershner DW, Bray P, et al.: Interaction of hemostatic genetics with hormone therapy: new insights to explain arterial thrombosis in postmenopausal women. Chest 2002, 121:906–920. Glueck CJ, Wang P, Fontaine RN, et al.: Effect of exogenous estrogen on atherothrombotic vascular disease risk related to the presence or absence of the factor V Leiden mutation (resistance to activated protein C). Am J Cardiol 1999, 84:549–554. Rossouw JE: Hormones, genetic factors, and gender differences in cardiovascular disease. Cardiovasc Res 2002, 53:550–557. Psaty BM, Smith NL, Lemaitre RN, et al.: Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarction in postmenopausal women. JAMA 2001, 285:906–913. Herrington DM, Brosnihan KB, Pusser BE, et al.: Differential effects of E and droloxifene on C-reactive protein and other markers of inflammation in healthy postmenopausal women. J Clin Endocrinol Metab 2001, 86:4216–4222. Ridker PM, Hennekens CH, Rifai N, Buring JE, Manson JE: Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 1999, 100:713–716. Wingrove CS, Garr E, Godsland IF, Stevenson JC: 17beta-oestradiol enhances release of matrix metalloproteinase-2 from human vascular smooth muscle cells. Biochim Biophys Acta 1998, 1406:169–174. Cannon R, Yang BK, Ardans J: Increased serum matrix metalloproteinase-9 expression in postmenopausal women on estrogen therapy [abstract]. J Am Coll Cardiol 1995, 35(suppl 2):303. Fuster V, Badimon J, Chesebro JH, Fallon JT: Plaque rupture, thrombosis, and therapeutic implications. Haemostasis 1996, 26(suppl 4):269–284. Walsh BW, Schiff I, Rosner B, et al.: Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 1991, 325:1196–1204. Gaziano JM, Hennekens CH, O’Donnell CJ, Breslow JL, Buring JE: Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. Circulation 1997, 96:2520–2525. Col NF, Pauker SG, Goldberg RJ, et al.: Individualizing therapy to prevent long-term consequences of estrogen deficiency in postmenopausal women. Arch Intern Med 1999, 159:1458–1466. Stampfer MJ, Colditz GA: Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991, 20:47–63. Grady D, Rubin SM, Petitti DB, et al.: Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992, 117:1016–1037. Grodstein F, Stampfer M: The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Prog Cardiovasc Dis 1995, 38:199–210. Grodstein F, Manson JE, Colditz GA, et al.: A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000, 133:933–941. Sullivan JM, Vander Zwaag R, Lemp GF, et al.: Postmenopausal estrogen use and coronary atherosclerosis. Ann Intern Med 1988, 108:358–363. Sullivan JM: Coronary arteriography in estrogen-treated postmenopausal women. Prog Cardiovasc Dis 1995, 38:211–222. Grodstein F, Manson JE, Stampfer MJ: Postmenopausal hormone use and secondary prevention of coronary events in the nurses’ health study a prospective, observational study. Ann Intern Med 2001, 135:1–8. Wenger NK, Knatterud GL, Canner PL: Early risks of hormone therapy in patients with coronary heart disease. JAMA 2000, 284:41–43. Alexander KP, Newby LK, Hellkamp AS, et al.: Initiation of hormone replacement therapy after acute myocardial infarction is associated with more cardiac events during follow-up. J Am Coll Cardiol 2001, 38:1–7. Heckbert SR, Kaplan RC, Weiss NS, et al.: Risk of recurrent coronary events in relation to use and recent initiation of postmenopausal hormone therapy. Arch Intern Med 2001, 161:1709–1713. Matthews KA, Kuller LH, Wing RR, Meilahn EN, Plantinga P: Prior to use of estrogen replacement therapy, are users healthier than nonusers? Am J Epidemiol 1996, 143:971–978. Mosca L: Estrogen and atherosclerosis. J Invest Med 1998, 46:381–386. Hulley S, Grady D, Bush T, et al.: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998, 280:605–613. Herrington DM, Reboussin DM, Brosnihan KB, et al.: Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000, 343:522–529. Schulman S, Thiemann D, Ouyang P, et al.: Effects of acute hormone therapy on recurrent ischemia in postmenopausal women with unstable angina. J Am Coll Cardiol 2001, 37:648A. Clarke S, Kelleher J, Lloyd-Jones H: Transdermal hormone replacement therapy for the secondary prevention of coronary artery disease in postmenopausal women [abstract]. Eur Heart J 2000, 21:212. Viscoli CM, Brass LM, Kernan WN, et al.: A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 2001, 345:1243–1249. Pettiti DB: Hormone replacement therapy and heart disease prevention: experimentation trumps observation [editorial]. JAMA 1998, 280:650–652. Post WS, Goldschmidt-Clermont PJ, Wilhide CC, et al.: Methylation of the estrogen receptor gene is associated with aging and atherosclerosis in the cardiovascular system. Cardiovasc Res 1999, 43:985–991. Dollar AL, Kragel AH, Fernicola DJ, Waclawiw MA, Roberts WC: Composition of atherosclerotic plaques in coronary arteries in women less than 40 years of age with fatal coronary artery disease and implications for plaque reversibility. Am J Cardiol 1991, 67:1223–1227. Hodis HN, Mack WJ, Lobo RA, et al.: Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001, 135:939–953. Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002, 288:321–333. Gruber CJ, Tschugguel W, Schneeberger C, Huber JC: Production and actions of estrogens. N Engl J Med 2002, 346:340–352. Ansbacher R: The pharmacokinetics and efficacy of different estrogens are not equivalent. Am J Obstet Gynecol 2001, 184:255–263. Meschia M, Bruschi F, Soma M, et al.: Effects of oral and transdermal hormone replacement therapy on lipoprotein(A) and lipids: a randomized controlled trial. Menopause 1998, 5:157–162. Vehkavaara S, Hakala-Ala-Pietila T, Virkamaki A, et al.: Differential effects of oral and transdermal estrogen replacement therapy on endothelial function in postmenopausal women. Circulation 2000, 102:2687–2693. Lobo RA, Bush T, Carr BR, Pickar JH: Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism. Fertil Steril 2001, 76:13–24. Dewell A, Hollenbeck CB, Bruce B: The effects of soy-derived phytoestrogens on serum lipids and lipoproteins in moderately hypercholesterolemic postmenopausal women. J Clin Endocrinol Metab 2002, 87:118–121. Clarkson TB: Soy, soy phytoestrogens and cardiovascular disease. J Nutr 2002, 132:566S-569S. Anderson JW, Johnstone BM, Cook-Newell ME: Meta-analysis of the effects of soy protein intake on serum lipids [comment]. N Engl J Med 1995, 333:276–282. Ruiz-Larrea MB, Mohan AR, Paganga G, et al.: Antioxidant activity of phytoestrogenic isoflavones. Free Radic Res 1997, 26:63–70. Cummings SR, Eckert S, Krueger KA, et al.: The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999, 281:2189–2197. Khovidhunkit W, Shoback DM: Clinical effects of raloxifene hydrochloride in women. Ann Intern Med 1999, 130:431–439. Clarke SC, Schofield PM, Grace AA, Metcalfe JC, Kirschenlohr HL: Tamoxifen effects on endothelial function and cardiovascular risk factors in men with advanced atherosclerosis. Circulation 2001, 103:1497–1502. Blum A, Schenke WH, Hathaway L, et al.: Effects of estrogen and the selective estrogen receptor modulator raloxifene on markers of inflammation in postmenopausal women. Am J Cardiol 2000, 86:892–895. Saitta A, Altavilla D, Cucinotta D, et al.: Randomized, double-blind, placebo-controlled study on effects of raloxifene and hormone replacement therapy on plasma no concentrations, endothelin-1 levels, and endothelium-dependent vasodilation in postmenopausal women. Arterioscler Thromb Vasc Biol 2001, 21:1512–1519. Rutqvist LE, Mattsson A: Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group. J Natl Cancer Inst 1993, 85:1398–1406. McDonald CC, Alexander FE, Whyte BW, Forrest AP, Stewart HJ: Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. The Scottish Cancer Trials Breast Group. BMJ 1995, 311:977–980. McDonald CC, Stewart HJ: Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee. BMJ 1991, 303:435–437. Barrett-Connor E, Grady D, Sashegyi A, et al.: Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 2002, 287:847–857. Mosca L: Rationale and overview of the Raloxifene Use for the Heart (RUTH) trial. Ann N Y Acad Sci 2001, 949:181–185. Cummings DM: Postmenopausal hormone replacement therapy. Clin Fam Pract 2002, 4:135–154. Harlap S: The benefits and risks of hormone replacement therapy: an epidemiologic overview. Am J Obstet Gynecol 1992, 166(6 Pt 2):1986–1992. Grodstein F, Stampfer MJ, Falkeborn M, Naessen T, Persson I: Postmenopausal hormone therapy and risk of cardiovascular disease and hip fracture in a cohort of Swedish women. Epidemiology 1999, 10:476–480. Miyagawa K, Rosch J, Stanczyk F, Hermsmeyer K: Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm. Nat Med 1997, 3:324–327. Koh KK, Jin DK, Yang SH, et al.: Vascular effects of synthetic or natural progestagen combined with conjugated equine estrogen in healthy postmenopausal women. Circulation 2001, 103:1961–1966. Pike MC, Spicer DV, Dahmoush L, Press MF: Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 1993, 15:17–35. Tanis BC, van den Bosch MA, Kemmeren JM, et al.: Oral contraceptives and the risk of myocardial infarction. N Engl J Med 2001, 345:1787–1793. Herrington DM, Howard TD, Hawkins GA, et al.: Estrogen-receptor polymorphisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease. N Engl J Med 2002, 346:967–974. Mikkola TS, Clarkson TB: Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc Res 2002, 53:605–619. Mosca L: The role of hormone replacement therapy in the prevention of postmenopausal heart disease. Arch Intern Med 2000, 160:2263–2272. Mosca L, Collins P, Herrington DM, et al.: Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 2001, 104:499–503. Manson J, Martin KA: Clinical practice: postmenopausal hormone replacement therapy. N Engl J Med 2001, 345:34–40. Fletcher SW, Colditz GA: Failure of estrogen plus progestin therapy for prevention. JAMA 2002, 288:366–368. Mosca L, Grundy SM, Judelson D, et al.: Guide to preventive cardiology for w women. AHA/ACC Scientific Statement Consensus panel statement. Circulation 1999, 99:2480–2484.